RT Journal Article
SR Electronic
T1 Disease waves of SARS-CoV-2 in Iran closely mirror global pandemic trends
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.23.21265086
DO 10.1101/2021.10.23.21265086
A1 Fattahi, Zohreh
A1 Mohseni, Marzieh
A1 Beheshtian, Maryam
A1 Jafarpour, Ali
A1 Jalalvand, Khadijeh
A1 Keshavarzi, Fatemeh
A1 Behravan, Hanieh
A1 Ghodratpour, Fatemeh
A1 Ashrafi, Farzane Zare
A1 Kalhor, Marzieh
A1 Azad, Maryam
A1 Koshki, Mahdieh
A1 Ghaziasadi, Azam
A1 Soveyzi, Mohamad
A1 Abdollahi, Alireza
A1 Kiani, Seyed Jalal
A1 Ataei-Pirkooh, Angila
A1 Rezaeiazhar, Iman
A1 Bokharaei-Salim, Farah
A1 Haghshenas, Mohammad Reza
A1 Babamahmoodi, Farhang
A1 Mokhames, Zakiye
A1 Soleimani, Alireza
A1 Elahi, Zohreh
A1 Ziaee, Masood
A1 Javanmard, Davod
A1 Ghafari, Shokouh
A1 Ezani, Akram
A1 AnsariMoghaddam, Alireza
A1 Shahraki-Sanavi, Fariba
A1 HashemiShahri, Seyed Mohammad
A1 Azaran, Azarakhsh
A1 Yousefi, Farid
A1 Moattari, Afagh
A1 Moghadami, Mohsen
A1 Fakhim, Hamed
A1 Ataei, Behrooz
A1 Nasri, Elahe
A1 Poortahmasebi, Vahdat
A1 Varshochi, Mojtaba
A1 Mojtahedi, Ali
A1 Jalilian, Farid
A1 khazeni, Mohammad
A1 Moradi, Abdolvahab
A1 Tabarraei, Alijan
A1 Piroozmand, Ahmad
A1 Yahyapour, Yousef
A1 Bayani, Masoumeh
A1 Tavangar, Fatemeh
A1 Yaghoubi, Mahmood
A1 Keramat, Fariba
A1 Tavakoli, Mahsa
A1 Jalali, Tahmineh
A1 Pouriayevali, Mohammad Hassan
A1 Salehi-Vaziri, Mostafa
A1 Khorram Khorshid, Hamid Reza
A1 Najafipour, Reza
A1 Malekzadeh, Reza
A1 Kahrizi, Kimia
A1 Jazayeri, Seyed Mohammad
A1 Najmabadi, Hossein
YR 2021
UL http://medrxiv.org/content/early/2021/10/25/2021.10.23.21265086.abstract
AB SARS-CoV-2 genome surveillance projects provide a good measure of transmission and monitor the circulating SARS-CoV-2 variants at regional and global scales. Iran is one of the most affected countries still involved with the virus circulating in at least five significant disease waves, as of September 2021. Complete genome sequencing of 50 viral isolates in an early phase of outbreak in Iran, shed light on the origins and circulating lineages at that time. As part of a genomic surveillance program, we provided an additional 319 complete genomes from October 2020 onwards. The current study is the report of complete SARS-CoV-2 genome sequences of Iran in the March 2020-May 2021 time interval. We aimed to characterize the genetic diversity of SARS-CoV-2 in Iran over one year.Overall, 35 different lineages and 8 clades were detected. Temporal dynamics of the prominent SARS-CoV-2 clades/lineages circulating in Iran is comparable to the global perspective and introduces the 19A clade (B.4) dominating the first disease wave, followed by 20A (B.1.36), 20B (B.1.1.413), 20I (B.1.1.7) clades, dominating second, third and fourth disease waves, respectively. We observed a mixture of circulating 20A (B.1.36), 20B (B.1.1.413), 20I (B.1.1.7) clades in winter 2021, paralleled in a diminishing manner for 20A/20B and a growing rise for 20I, eventually prompting the 4th outbreak peak. Furthermore, our study provides evidence on the entry of the Delta variant in April 2021, leading to the 5th disease wave in summer 2021.Three lineages are highlighted as hallmarks of SARS-CoV-2 outbreak in Iran; B4, dominating early periods of the epidemic, B.1.1.413 (specific B.1.1 lineage carrying a combination of [D138Y-S477N-D614G] spike mutations) in October 2020-February 2021, and the co-occurrence of [I100T-L699I] spike mutations in half of B.1.1.7 sequences mediating the fourth peak.Continuous monthly monitoring of SARS-CoV-2 genome mutations led to the detection of 1577 distinct nucleotide mutations, in which the top recurrent mutations were D614G, P323L, R203K/G204R, 3037C>T, and 241C>T; the renowned combination of mutations in G and GH clades. The most frequent spike mutation is D614G followed by 13 other frequent mutations based on the prominent circulating lineages; B.1.1.7 (H69_V70del, Y144del, N501Y, A570D, P681H, T716I, S982A, D1118H, I100T, and L699I), B.1.1.413 (D138Y, S477N) and B.1.36 (I210del).In brief, mutation surveillance in this study provided a real-time comprehensive picture of the SARS-CoV-2 mutation profile in Iran, which is beneficial for evaluating the magnitude of the epidemic and assessment of vaccine and therapeutic efficiency in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Iran Vice deputy for Research and Technology at the Iran Ministry of Health and Medical Education, grant number: 99/801/A/6/25942.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee at the University of Social Welfare & Rehabilitation Sciences gave ethical approval for this work (Approval number: IR.USWR.REC.1399.207).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost of the sequence data provided through this study are already uploaded in the GISAID database (https://www.gisaid.org/) and the remaining is going to be submitted. https://www.gisaid.org/